Autoimmune Axonal Evaluation
Test in Focus
Mayo Clinic Laboratories utilizes a comprehensive, phenotypic testing approach to evaluate for antibodies associated with autoimmune axonal neuropathy. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Divyanshu Dubey, M.B.B.S., discusses the serological panel, which uses multiple methodologies to detect for nine distinct antibodies.
“All of the antibodies included in this panel are of significant relevance to patients with neuropathy,” Dr. Dubey says. “They not only provide information about the underlying etiology of neuropathy, they also point us towards if there’s an underlying cancer. They help us with having discussions with patients about the natural history of the disease and coming up with the best treatment regimen.”
The phenotype-specific approach to antibody evaluation is an improvement on previous approaches. All relevant antibodies are included, not just those associated with cancer, and an improved methodology for several important tests helps improve specificity.
“We are adapting our evaluations to the growing science behind antibody reporting, discovery, and utilization,” Dr. Dubey says. “We are trying to make sure that if a patient is presenting with one particular syndrome or predominant neurological phenotype, we are covering all potential autoantibodies that are paraneoplastic or autoimmune."
Listen to learn more about how comprehensive testing for autoimmune axonal neuropathies can provide clarity on a complicated condition.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 4 mL
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.